Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. (ARQT) Stock Overview
Explore Arcutis Biotherapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
2.9B
P/E Ratio
-187.76
EPS (TTM)
$-0.13
ROE
-0.10%
ARQT Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Arcutis Biotherapeutics, Inc. (ARQT) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 50.17, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $34.39.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -187.76 and a market capitalization of 2.9B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.